Biodegradable material microsphere blood vessel suppository containing liposome cell factor and its preparation and uses

Abstract

The invention discloses the degradable biomaterial microsphere vessel suppository and preparing method. The method comprises the following steps: extracting polysaccharose sodium salt or gelatin from natural agonic acid, using immunocyte factor, such as interleukins-2, tumor necrosis factor and interferon, as presidium, making liposome cytokine micro spheres whose sizes are 50 mum-75 mum, 75 mum-150 mum, 100 mum-200 mum, 200 mum-300 mum, 200 mum-450 mum, 100 mum-300 mum, 300 mum-500 mum, 500 mum-700 mum, and 700 mum-900 mum. The degradable biomaterial microsphere vessel suppository can be used to cure late hepatic carcinoma, kidney cancer, bladder cancer, carcinoma of colon, and other carcinoma arterial embolisms.

Description

technical field [0001] The present invention relates to a vascular embolic agent of biodegradable materials and its preparation and application, in particular to polysaccharide sodium salt or gelatin coated with lipid which is extracted from natural plant alginic acid and has good biodegradability and biocompatibility. Cytokines wrapped in plastids, made into microspheres of 50μm-75μm, 75μm-150μm, 100μm-200μm, 200μm-300μm, 200μm-450μm, 100μm-300μm, 300μm-500μm, 500μm-700μm, 700μm-900μm microspheres, used for Tumor arterial embolization and locally targeted immunochemotherapy. Background technique [0002] Tumor arterial embolization therapy is a new therapy that injects embolic substances into the arterioles dominating the cancer tissue to cause mechanical embolization of the arterioles, thereby inhibiting tumor growth. In 1981, Kato first proposed chemoembolization, which combined chemotherapy drugs and embolic substances effectively and organically, and proposed a new met...

AI Technical Summary

Problems solved by technology

[0012] Due to the use of cytokines and their application in the body can produce many adverse reactions, limiting its clinical application

IL-2 has a short half-life in the body and poor stability. The clinical application of large doses can lead to systemic side effects such as liver and kidney dysfunction and pulmonary capillary leak syndrome.

Images